Skip directly to content

Improving Medical and Patient Education in Haemato-Oncology in Post COVID-19 Era

Pfizer is now inviting applications from UK healthcare organisations for a Quality Improvement Grant to support “2020 Oncology UK: Continuity in Care for Patients with Cancer During COVID-19 Pandemic” Competitive Grant Programme.
 

We are particularly interested in receiving proposals that:

  • Development of online educational content for patients
  • Multi-disciplinary simulation education around effective tele/video services
  • Educational content on effective virtual multi-disciplinary meetings
  • Topics around how to train junior doctors in oncology and haematology in a virtual world
  • Education on the effective utilisation of tools designed to facilitate remote interaction between patients and HCPs

 

Proposals for projects covering the following areas are out of scope of this call:

  • Projects bearing the name or class of specific medicines
  • Projects designed to increase the uptake of a single therapeutic agent or intervention (projects should be aimed at improving adherence to specific guidelines or patient pathways)
  • Applications for funding of services which should be provided as standard within the NHS
  • Interventional or observational clinical studies
  • In vitro or in vivo (animal) studies
  • Non-interventional studies, such as epidemiological studies
  • Outcomes research studies where the primary focus is to understand the results of particular health care practices and interventions as well as to monitor and improve the quality of care
  • Other types of independent research on disease states, including novel diagnostic screening tools and surveys

 

Pfizer processes these applications through the Pfizer Global Medical Grants System which enables the review and consideration of an individual grant request submission from a health care organisation. This is intended to support an independent medical and/or scientific initiative for quality improvement and to improve patient outcomes, in an area of unmet medical need that is aligned with Pfizer’s medical and/or scientific strategies.

For all independent grants, the grant requester and the health care organisation grantee are responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the initiative.

Applications for this Call will be accepted between 3rd September 2020 and 6th October 2020. Applications are anticipated to be judged by 28th October 2020. The total amount of funding available for this Call will be £150,000.  There is no cap on the number of projects to be funded. Expected range of grant requests under this RFP is approximately £5,000 to £50,000.  Individual projects requesting up to a maximum of £50,000 will be considered.  Grant applications will be reviewed by Pfizer colleagues that hold relevant medical and compliance positions within the organisation.

Grants will be awarded on a 'competitive basis', subject to the criteria set out in the Call for Continuity in Care for Patients with Cancer During COVID-19 Pandemic, which also contains the full details of this call.

 

Apply for Continuity in Care for Patients with Cancer During COVID-19 Pandemic

Note: First-time users will need to use their health care organisation / NHS email address and Create a password.

If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the log-in webpage.

To contact Pfizer for any other purpose, including adverse event reports, medical information requests, or data protection enquiries please call 01304 616161.

PP-ONC-GBR-1573 / August 2020